Search

Search Constraints

You searched for: Author/Creator Pratley, Richard E.

Search Results

1. A Novel Endocrine Role for the BAT-Released Lipokine 12, 13-diHOME to Mediate Cardiac Function. Issue 2 (12th January 2021)

3. An improvement in skeletal muscle mitochondrial capacity with short‐term aerobic training is associated with changes in Tribbles 1 expression. Issue 12 (19th June 2020)

4. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Issue 11 (9th August 2021)

5. Assessing the Pathophysiology of Hyperglycemia in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium. Issue 6 (July 2022)

6. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. Issue 5 (4th February 2018)

7. Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Issue 4 (17th January 2023)

8. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Issue 11 (13th August 2019)

9. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin. Issue 3 (26th December 2022)

10. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV. Issue 7 (29th March 2022)